ADVM earnings call for the period ending March 31, 2020.
News & Analysis: Adverum Biotechnologies, Inc.
AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.
The company's experimental gene therapy for a common cause of blindness showed promise in a clinical trial.
Adverum's lead gene therapy candidate continues to impress in its early-stage trial.
ADVM earnings call for the period ending December 31, 2019.
Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.
Here's how they could keep on rocketing higher.
ADVM earnings call for the period ending September 30, 2019.
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
Even on an up day for the stock market, these companies lost a lot of ground.